Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Paisseur centrale de la cornée chez le patients atteints d’acromégalie

Central Corneal Thickness in patients with acromegaly

Introduction Acromegaly is hormonal disorder caused by excessive growth hormone (GH) by the pituitary gland, this results in anatomical changes in many organs and also in the eye and specially in cornea. Objective To perform a connection between the disease activity and the corneal changes Matériels et Méthodes In 28 patients with acromegaly and in 22 voluntary healthy the central corneal thickness (CCT) was measured by pachymeter. And the patients were divided in 2 groups: the first (“group A”) contains 13 cases with not controlled acromegaly; and the other one (“group B”) is related to 15 patients with controlled acromegaly Résultats Patients with acromegaly have a central corneal thickne…